vs
ENNIS, INC.（EBF）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是ENNIS, INC.的2.0倍（$197.9M vs $100.2M），ENNIS, INC.净利率更高（10.8% vs 6.7%，领先4.1%），REPLIGEN CORP同比增速更快（13.6% vs 0.4%），REPLIGEN CORP自由现金流更多（$17.6M vs $15.7M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 1.4%）
ENNIS, INC.是北美领先的商业印刷产品及相关服务供应商，提供定制商业单据、压敏标签、营销宣传物料、促销品、品牌包装等产品，服务覆盖零售、医疗、金融服务及中小企业等多个领域的客户。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
EBF vs RGEN — 直观对比
营收规模更大
RGEN
是对方的2.0倍
$100.2M
营收增速更快
RGEN
高出13.2%
0.4%
净利率更高
EBF
高出4.1%
6.7%
自由现金流更多
RGEN
多$1.8M
$15.7M
两年增速更快
RGEN
近两年复合增速
1.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $100.2M | $197.9M |
| 净利润 | $10.8M | $13.3M |
| 毛利率 | 31.9% | 52.5% |
| 营业利润率 | 15.0% | 9.0% |
| 净利率 | 10.8% | 6.7% |
| 营收同比 | 0.4% | 13.6% |
| 净利润同比 | 6.1% | 143.9% |
| 每股收益（稀释后） | $0.42 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBFRGEN
| Q4 25 | $100.2M | $197.9M | ||
| Q3 25 | $98.7M | $188.8M | ||
| Q2 25 | $97.2M | $182.4M | ||
| Q1 25 | $92.7M | $169.2M | ||
| Q4 24 | $99.8M | $174.1M | ||
| Q3 24 | $99.0M | $154.9M | ||
| Q2 24 | $103.1M | $154.1M | ||
| Q1 24 | $97.4M | $151.3M |
净利润EBFRGEN
| Q4 25 | $10.8M | $13.3M | ||
| Q3 25 | $13.2M | $14.9M | ||
| Q2 25 | $9.8M | $14.9M | ||
| Q1 25 | $9.0M | $5.8M | ||
| Q4 24 | $10.2M | $-30.3M | ||
| Q3 24 | $10.3M | $-654.0K | ||
| Q2 24 | $10.7M | $3.3M | ||
| Q1 24 | $10.1M | $2.1M |
毛利率EBFRGEN
| Q4 25 | 31.9% | 52.5% | ||
| Q3 25 | 30.5% | 53.2% | ||
| Q2 25 | 31.1% | 50.0% | ||
| Q1 25 | 29.5% | 53.6% | ||
| Q4 24 | 29.3% | 26.1% | ||
| Q3 24 | 30.1% | 50.0% | ||
| Q2 24 | 30.0% | 49.8% | ||
| Q1 24 | 28.4% | 49.5% |
营业利润率EBFRGEN
| Q4 25 | 15.0% | 9.0% | ||
| Q3 25 | 12.5% | 8.9% | ||
| Q2 25 | 13.7% | 7.6% | ||
| Q1 25 | 13.0% | 3.9% | ||
| Q4 24 | 13.1% | -17.7% | ||
| Q3 24 | 13.3% | -5.1% | ||
| Q2 24 | 13.3% | 1.0% | ||
| Q1 24 | 13.3% | 1.3% |
净利率EBFRGEN
| Q4 25 | 10.8% | 6.7% | ||
| Q3 25 | 13.3% | 7.9% | ||
| Q2 25 | 10.1% | 8.2% | ||
| Q1 25 | 9.7% | 3.4% | ||
| Q4 24 | 10.2% | -17.4% | ||
| Q3 24 | 10.4% | -0.4% | ||
| Q2 24 | 10.4% | 2.2% | ||
| Q1 24 | 10.4% | 1.4% |
每股收益（稀释后）EBFRGEN
| Q4 25 | $0.42 | $0.24 | ||
| Q3 25 | $0.51 | $0.26 | ||
| Q2 25 | $0.38 | $0.26 | ||
| Q1 25 | $0.34 | $0.10 | ||
| Q4 24 | $0.39 | $-0.55 | ||
| Q3 24 | $0.40 | $-0.01 | ||
| Q2 24 | $0.41 | $0.06 | ||
| Q1 24 | $0.39 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.3M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $304.8M | $2.1B |
| 总资产 | $354.3M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资EBFRGEN
| Q4 25 | $31.3M | $767.6M | ||
| Q3 25 | $31.9M | $748.7M | ||
| Q2 25 | $32.6M | $708.9M | ||
| Q1 25 | $72.5M | $697.2M | ||
| Q4 24 | $68.6M | $757.4M | ||
| Q3 24 | $122.6M | $784.0M | ||
| Q2 24 | $123.7M | $809.1M | ||
| Q1 24 | $110.9M | $780.6M |
总债务EBFRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EBFRGEN
| Q4 25 | $304.8M | $2.1B | ||
| Q3 25 | $305.4M | $2.1B | ||
| Q2 25 | $301.2M | $2.1B | ||
| Q1 25 | $302.0M | $2.0B | ||
| Q4 24 | $297.7M | $2.0B | ||
| Q3 24 | $358.4M | $2.0B | ||
| Q2 24 | $354.4M | $2.0B | ||
| Q1 24 | $349.8M | $2.0B |
总资产EBFRGEN
| Q4 25 | $354.3M | $2.9B | ||
| Q3 25 | $361.8M | $2.9B | ||
| Q2 25 | $361.7M | $2.9B | ||
| Q1 25 | $348.9M | $2.9B | ||
| Q4 24 | $346.1M | $2.8B | ||
| Q3 24 | $406.8M | $2.8B | ||
| Q2 24 | $406.2M | $2.9B | ||
| Q1 24 | $399.2M | $2.8B |
负债/权益比EBFRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.4M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $15.7M | $17.6M |
| 自由现金流率自由现金流/营收 | 15.7% | 8.9% |
| 资本支出强度资本支出/营收 | 0.7% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.52× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $42.5M | $93.9M |
8季度趋势，按日历期对齐
经营现金流EBFRGEN
| Q4 25 | $16.4M | $25.7M | ||
| Q3 25 | $10.5M | $48.1M | ||
| Q2 25 | $8.0M | $28.6M | ||
| Q1 25 | $12.8M | $15.0M | ||
| Q4 24 | $18.2M | $39.2M | ||
| Q3 24 | $11.8M | $49.3M | ||
| Q2 24 | $23.1M | $42.2M | ||
| Q1 24 | $16.6M | $44.7M |
自由现金流EBFRGEN
| Q4 25 | $15.7M | $17.6M | ||
| Q3 25 | $9.0M | $43.4M | ||
| Q2 25 | $6.6M | $21.5M | ||
| Q1 25 | $11.1M | $11.4M | ||
| Q4 24 | $17.5M | $33.6M | ||
| Q3 24 | $10.7M | $42.3M | ||
| Q2 24 | $20.6M | $37.4M | ||
| Q1 24 | $15.0M | $36.4M |
自由现金流率EBFRGEN
| Q4 25 | 15.7% | 8.9% | ||
| Q3 25 | 9.2% | 23.0% | ||
| Q2 25 | 6.8% | 11.8% | ||
| Q1 25 | 12.0% | 6.8% | ||
| Q4 24 | 17.6% | 19.3% | ||
| Q3 24 | 10.8% | 27.3% | ||
| Q2 24 | 20.0% | 24.3% | ||
| Q1 24 | 15.3% | 24.0% |
资本支出强度EBFRGEN
| Q4 25 | 0.7% | 4.1% | ||
| Q3 25 | 1.4% | 2.5% | ||
| Q2 25 | 1.4% | 3.9% | ||
| Q1 25 | 1.8% | 2.1% | ||
| Q4 24 | 0.6% | 3.2% | ||
| Q3 24 | 1.1% | 4.5% | ||
| Q2 24 | 2.4% | 3.1% | ||
| Q1 24 | 1.7% | 5.5% |
现金转化率EBFRGEN
| Q4 25 | 1.52× | 1.93× | ||
| Q3 25 | 0.80× | 3.23× | ||
| Q2 25 | 0.81× | 1.92× | ||
| Q1 25 | 1.41× | 2.57× | ||
| Q4 24 | 1.78× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 2.16× | 12.70× | ||
| Q1 24 | 1.63× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
